TCGA-FD-A62N-01A-11R-A30C-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 2.693823916
- os_event
- false
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.740
- INTERFERON_GAMMA_RESPONSE+0.700
- ALLOGRAFT_REJECTION+0.670
- IL6_JAK_STAT3_SIGNALING+0.580
- INFLAMMATORY_RESPONSE+0.580
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.550
- TNFA_SIGNALING_VIA_NFKB+0.520
- COMPLEMENT+0.490
- IL2_STAT5_SIGNALING+0.460
- ANGIOGENESIS+0.430
Top 10 suppressed
- PEROXISOME-0.190
- SPERMATOGENESIS-0.180
- PROTEIN_SECRETION-0.170
- BILE_ACID_METABOLISM-0.140
- FATTY_ACID_METABOLISM-0.130
- KRAS_SIGNALING_DN-0.090
- CHOLESTEROL_HOMEOSTASIS-0.070
- ADIPOGENESIS+0.000
- ANDROGEN_RESPONSE+0.030
- ESTROGEN_RESPONSE_EARLY+0.030
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_06AMMCXR | low-grade glioma | — | 0.911 |
| 2 | BS_KXMYBQ6N | EPN | EPN Tumor | 0.905 |
| 3 | SRR11296840 | — | — | 0.902 |
| 4 | R303 | — | — | 0.900 |
| 5 | 20050099.TNBC | — | D | 0.896 |
| 6 | BS_M85CXHDV | high-grade glioma | — | 0.893 |
| 7 | R317 | — | — | 0.892 |
| 8 | A3874F0D-53A9-43C8-87EE-65C12C0F8135 | — | — | 0.889 |
| 9 | MNG1029 | — | — | 0.889 |
| 10 | TCGA-FD-A5C1-01A-11R-A28M-07 | — | — | 0.889 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 42 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.740 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.700 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.670 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.580 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.580 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.550 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.520 | Inavolisib | — uncovered |
| COMPLEMENT | 0.490 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.460 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.430 | Remibrutinib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.420 | Inavolisib | — uncovered |
| APOPTOSIS | 0.400 | Idelalisib | — uncovered |
| COAGULATION | 0.400 | Binimetinib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.340 | Idelalisib | — uncovered |
| KRAS_SIGNALING_UP | 0.330 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| HYPOXIA | 0.280 | Idelalisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.280 | Idelalisib | — uncovered |